



**ASX Release**

**13 November 2025**

### **Acrux receives \$0.4 million advance on FY26 R&D Tax Incentive**

**Melbourne, Australia; Acrux Limited (ASX:ACR)** is pleased to announce it has received the first advance from Radium Capital in relation to its FY26 R&D Tax Incentive (RDTI). This advance totals \$0.4 million and broadly represents 80% of the estimated RDTI for the three months to 30 September 2025.

Acrux has used this short term funding facility for several years to give early access to the RDTI rebate. This advance incurs an interest charge at an annual rate of 17% and is secured against the FY26 RDTI rebate which we expect to be received from the Australian Tax Office later in 2026.

Funds will be used to support the progression of Acrux's development products and management of working capital.

Authorised for release by the Board of Acrux Limited.

#### **About Acrux**

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. For further information on Acrux, visit: [www.acrux.com.au](http://www.acrux.com.au)

**For more information, please contact:**

**John Warmbrunn**

**CEO & Managing Director**

**Acrux Limited**

P: + 61 3 8379 0100

E: [john.warmbrunn@acrux.com.au](mailto:john.warmbrunn@acrux.com.au)